GlassScriptPhysician profile
Jonathan D Gildin
NPI 1972804557
$3,102.68
in general payments reported to CMS, 2019-2025
14 companies · $904 in 2025
The $904 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $675 · 2023: $737 · 2024: $93.67 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $888.28 | 2023-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Getinge USA Sales, LLC | $548.47 | 2021-2025 | Cardiohelp, Vasoview Hemopro 2, Vasoview Hemopro 2 |
| Baxter Healthcare | $272.43 | 2021-2023 | Floseal |
| Horizon Therapeutics Plc | $250.00 | 2021-2023 | Uplizna |
| Lsi Solutions INC | $157.51 | 2022-2023 | Cor Knot |
| Terumo Cardiovascular Systems Corporation | $147.81 | 2021 | |
| Novo Nordisk INC | $125.01 | 2022 | |
| Amgen INC. | $125.00 | 2022 | |
| Glaxosmithkline, LLC. | $125.00 | 2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.98 | 2023 | |
| Janssen Scientific Affairs, LLC | $120.00 | 2022 | |
| Abbvie INC. | $101.19 | 2021 | |
| Genzyme Corporation | $100.00 | 2025 | |
| Abiomed | $20.00 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gildin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.